Clindamycin Palmitate Hydrochloride
A palmitate ester prodrug of clindamycin formulated as a pediatric oral suspension that is converted to active clindamycin in the body. The ester masking improves palatability while the hydrochloride salt aids solubility.
Moleküler Ağırlık
699,9000 g/mol
TPSA
134,00 Ų
Terapötik Alanlar
Etki Mekanizması
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
2D Yapı
Cite this structure
Embed this structure
SMILES
CCCCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](O)[C@@H](O)[C@@H]([C@H](NC(=O)[C@@H]2C[C@@H](CCC)CN2C)[C@H](C)Cl)O[C@@H]1SC.Cl
InChI
InChI=1S/C34H63ClN2O6S.ClH/c1-6-8-9-10-11-12-13-14-15-16-17-18-19-21-27(38)42-32-30(40)29(39)31(43-34(32)44-5)28(24(3)35)36-33(41)26-22-25(20-7-2)23-37(26)4;/h24-26,28-32,34,39-40H,6-23H2,1-5H3,(H,36,41);1H/t24-,25+,26-,28+,29+,30-,31+,32+,34+;/m0./s1
Molecular Formula
C34H64Cl2N2O6S
HBD / HBA
4 / 8
Döndürülebilir Bağlar
23
Ağır Atomlar
45
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
A palmitate ester prodrug of clindamycin formulated as a pediatric oral suspension that is converted to active clindamycin in the body. The ester masking improves palatability while the hydrochloride salt aids solubility.
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Yes, Clindamycin Palmitate Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200632. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 16052038. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="clindamycin-palmitate-hydrochloride"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/clindamycin-palmitate-hydrochloride/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/clindamycin-palmitate-hydrochloride/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/clindamycin-palmitate-hydrochloride/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="clindamycin-palmitate-hydrochloride"></drugfyi-drug>